Protagonist Therapeutics Inc
PTGX56.070USD
+1.080+1.96%
Handelsschluss 08/15, 16:00（ET）Kurse um 15 Minuten verzögert
3.47BMarktkapitalisierung
10.01KGV TTM
mehr Informationen über Protagonist Therapeutics Inc Unternehmen
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).
Unternehmensinformationen
BörsenkürzelPTGX
Name des UnternehmensProtagonist Therapeutics Inc
IPO-datumAug 11, 2016
CEODr. Dinesh V. Patel, Ph.D.
Anzahl der mitarbeiter126
WertpapierartOrdinary Share
GeschäftsjahresendeAug 11
Addresse7707 Gateway Blvd Ste 140
StadtNEWARK
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl94560-1160
Telefon15104740170
Websitehttps://www.protagonist-inc.com/
BörsenkürzelPTGX
IPO-datumAug 11, 2016
CEODr. Dinesh V. Patel, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
314.22K
-12.00%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+6.14%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+38.31%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-26.51%
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
Ms. Sarah A. O'Dowd
Ms. Sarah A. O'Dowd
Independent Director
Independent Director
--
-100.00%
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Mr. Corey Davis, Ph.D.
Mr. Corey Davis, Ph.D.
IR Contact Officer
IR Contact Officer
--
--
Dr. Lewis T. Williams ,M.D., Ph.D.
Dr. Lewis T. Williams ,M.D., Ph.D.
Independent Director
Independent Director
--
-100.00%
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
314.22K
-12.00%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+6.14%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+38.31%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-26.51%
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 16
Aktualisiert: Sat, Aug 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
13.60%
Farallon Capital Management, L.L.C.
9.92%
RTW Investments L.P.
9.25%
The Vanguard Group, Inc.
6.99%
Deep Track Capital LP
5.22%
Andere
55.03%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
13.60%
Farallon Capital Management, L.L.C.
9.92%
RTW Investments L.P.
9.25%
The Vanguard Group, Inc.
6.99%
Deep Track Capital LP
5.22%
Andere
55.03%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
39.47%
Hedge Fund
29.91%
Investment Advisor/Hedge Fund
28.71%
Research Firm
4.59%
Venture Capital
4.14%
Private Equity
1.85%
Pension Fund
1.11%
Individual Investor
1.03%
Bank and Trust
0.37%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
533
68.00M
109.30%
-9.94M
2025Q1
541
67.25M
108.51%
-8.96M
2024Q4
503
65.58M
106.87%
-12.21M
2024Q3
480
64.24M
108.98%
-11.36M
2024Q2
419
61.14M
104.21%
-15.61M
2024Q1
412
61.98M
106.36%
-12.46M
2023Q4
402
59.53M
103.21%
-16.02M
2023Q3
400
59.06M
102.70%
-14.36M
2023Q2
411
59.30M
103.68%
-17.88M
2023Q1
397
55.80M
108.46%
-12.55M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
8.60M
13.87%
-162.95K
-1.86%
Mar 31, 2025
Farallon Capital Management, L.L.C.
6.11M
9.85%
+177.00K
+2.98%
Mar 31, 2025
RTW Investments L.P.
5.72M
9.23%
+220.87K
+4.02%
Mar 31, 2025
The Vanguard Group, Inc.
4.27M
6.88%
+57.18K
+1.36%
Mar 31, 2025
Deep Track Capital LP
3.25M
5.24%
+250.00K
+8.33%
Apr 03, 2025
BVF Partners L.P.
3.21M
5.18%
+636.03K
+24.70%
Jun 09, 2025
State Street Global Advisors (US)
2.71M
4.37%
-624.44K
-18.75%
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
2.45M
3.95%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
1.42M
2.3%
+46.50K
+3.38%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Wed, Aug 6
Aktualisiert: Wed, Aug 6
Name
Anteil
Invesco Biotechnology & Genome ETF
3.16%
Invesco Dorsey Wright Healthcare Momentum ETF
2.45%
ALPS Medical Breakthroughs ETF
2.31%
Invesco S&P SmallCap Health Care ETF
2.25%
Invesco S&P SmallCap 600 Pure Growth ETF
2.08%
ETC 6 Meridian Small Cap Equity ETF
1.57%
SPDR S&P Biotech ETF
1.09%
Cambria Value and Momentum ETF
0.94%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
Direxion Daily S&P Biotech Bull 3X Shares
0.7%
Mehr Anzeigen
Invesco Biotechnology & Genome ETF
Anteil3.16%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil2.45%
ALPS Medical Breakthroughs ETF
Anteil2.31%
Invesco S&P SmallCap Health Care ETF
Anteil2.25%
Invesco S&P SmallCap 600 Pure Growth ETF
Anteil2.08%
ETC 6 Meridian Small Cap Equity ETF
Anteil1.57%
SPDR S&P Biotech ETF
Anteil1.09%
Cambria Value and Momentum ETF
Anteil0.94%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.88%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.7%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
